Novartis halts development of ALS drug VHB937 after Phase 2 study fails to meet endpoints

智通财经2026/09/16 15:56

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Novartis (NVS.US): VHB937 did not meet its primary and secondary endpoints. Based on results from the Phase 2 ASTRALS study, development of VHB937 for amyotrophic lateral sclerosis (ALS) has been discontinued.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Novartis halts development of ALS drug VHB937 after Phase 2 study fails to meet endpoints

You may also like

Crypto prices